Therapeutic response to octreotide in patients with refractory CPT-11 induced diarrhea
- PMID: 11561696
- DOI: 10.1023/a:1010678214152
Therapeutic response to octreotide in patients with refractory CPT-11 induced diarrhea
Abstract
Purpose: Severe diarrhea can represent a dose-limiting toxicity with the use of CPT-11. Conventional therapy is ineffective in some patients and is also limited by patient compliance. We report our observation on the effectiveness of octreotide acetate in the treatment of CPT-11-induced diarrhea refractory to opioids.
Patients and methods: We describe 4 patients with metastatic gastrointestinal tumors who developed severe diarrhea following treatment with CPT-11 (65-125 mg/m2/weekly for 4 weeks every 6 weeks). Diarrhea was refractory to treatment with loperamide and diphenoxylate and was treated with octreotide acetate.
Results: Complete resolution of diarrhea was observed within 2-4 days of octreotide acetate treatment. Three patients responded to SC octreotide given every 8 hours and the 4th patient to octreotide given by continuous s.c. infusion.
Conclusions: Our preliminary observation suggests value of octreotide in the control of CPT-11 induced refractory diarrhea. Prospective studies are warranted.
Similar articles
-
Control of irinotecan-induced diarrhea by octreotide after loperamide failure.Support Care Cancer. 2001 Jun;9(4):258-60. doi: 10.1007/s005200000220. Support Care Cancer. 2001. PMID: 11430421
-
Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment.J Clin Oncol. 1998 Aug;16(8):2745-51. doi: 10.1200/JCO.1998.16.8.2745. J Clin Oncol. 1998. PMID: 9704727 Clinical Trial.
-
Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.J Clin Oncol. 1995 Jan;13(1):210-21. doi: 10.1200/JCO.1995.13.1.210. J Clin Oncol. 1995. PMID: 7799022 Clinical Trial.
-
[Chemotherapy-induced diarrhea].Gan To Kagaku Ryoho. 2003 Jun;30(6):765-71. Gan To Kagaku Ryoho. 2003. PMID: 12852342 Review. Japanese.
-
CPT-11. The European experience.Ann N Y Acad Sci. 1996 Dec 13;803:282-91. doi: 10.1111/j.1749-6632.1996.tb26398.x. Ann N Y Acad Sci. 1996. PMID: 8993522 Review.
Cited by
-
Systematic review of agents for the management of gastrointestinal mucositis in cancer patients.Support Care Cancer. 2013 Jan;21(1):313-26. doi: 10.1007/s00520-012-1644-z. Epub 2012 Nov 10. Support Care Cancer. 2013. PMID: 23142924
-
HuangQin Decoction Attenuates CPT-11-Induced Gastrointestinal Toxicity by Regulating Bile Acids Metabolism Homeostasis.Front Pharmacol. 2017 Mar 30;8:156. doi: 10.3389/fphar.2017.00156. eCollection 2017. Front Pharmacol. 2017. PMID: 28424615 Free PMC article.
-
Saccharic acid 1.4-lactone protects against CPT-11-induced mucosa damage in rats.J Cancer Res Clin Oncol. 2004 Jul;130(7):388-94. doi: 10.1007/s00432-004-0557-8. J Cancer Res Clin Oncol. 2004. PMID: 15160289 Free PMC article.
-
Resolution of refractory chemotherapy-induced diarrhea (CID) with octreotide long-acting formulation in cancer patients: 11 case studies.Support Care Cancer. 2004 Aug;12(8):561-70. doi: 10.1007/s00520-003-0507-z. Epub 2004 May 25. Support Care Cancer. 2004. PMID: 15160318
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical